Spencer Pharmaceutical Inc.

OTC: SPPH · Healthcare · Medical - Pharmaceuticals

PublicHQ Boston, Reports USD

#1143 of 1,394 Healthcare companies by revenuebottom-decile growth

EA Score

——

FH —DQ —GM —SS 10

v0.1 · 5/100 weight · pillars only

↑ balance-sheet leverage, return on assets · ↓ revenue growth (YoY), workforce scale

Methodology →

Revenue TTM

$670.2k

Rev growth YoY (TTM)

-69.5%

Net income (FY)

-$862.5k

Employees

Market cap

$29.4k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02003

Net income-$862.5k-$862.5k2003

Operating income$862.5k$862.5k2003

Total assets$4.2M$4.2M2003

Liabilities$379.6k$379.6k2003

Equity$3.9M$3.9M2003

Revenue trend

FY2001 – FY2003 · USD

$941.4k

FY01

$2.6M

FY02

FY03

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Spencer Pharmaceutical Inc. booked $0 in FY2003 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Transnational Cannabis Ltd.——Quick-Med Technologies, Inc.——Pressure BioSciences, Inc.——Braxia Scientific Corp.——

Key facts

CEOMaximilien Arella

SectorHealthcare

IndustryMedical - Pharmaceuticals

HeadquartersBoston, null

ExchangeOTC: SPPH

Employees2

IPO date2023-02-07

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.